fingolimod hydrochloride has been researched along with Rett Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Frasca, A; Korte, M; Landsberger, N; Patnaik, A; Spiombi, E; Zagrebelsky, M | 1 |
| Amann, M; Barde, YA; Barro, C; Datta, AN; Heesom, K; Kappos, L; Kuhle, J; Magon, S; Naegelin, Y; Ramelli, GP; Schädelin, S; Weber, P | 1 |
| Barde, YA; Dekkers, MP; Deogracias, R; Guy, J; Ionescu, MC; Vogt, KE; Yazdani, M | 1 |
3 other study(ies) available for fingolimod hydrochloride and Rett Syndrome
| Article | Year |
|---|---|
Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner.
Topics: Animals; Biomarkers; Brain-Derived Neurotrophic Factor; Dendritic Spines; Fingolimod Hydrochloride; Fluorescent Antibody Technique; Gene Expression; Gene Expression Regulation; Genes, fos; Immunosuppressive Agents; Mice; Pyramidal Cells; Rett Syndrome | 2020 |
Fingolimod in children with Rett syndrome: the FINGORETT study.
Topics: Adolescent; Child; Female; Fingolimod Hydrochloride; Humans; Methyl-CpG-Binding Protein 2; Neurodevelopmental Disorders; Rett Syndrome; Switzerland | 2021 |
Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome.
Topics: Animals; Astrocytes; Brain-Derived Neurotrophic Factor; Cell Death; Cells, Cultured; Disease Models, Animal; Excitatory Amino Acid Agonists; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; MAP Kinase Signaling System; Methyl-CpG-Binding Protein 2; Mice; Motor Activity; N-Methylaspartate; Neurons; Organ Culture Techniques; Pregnancy; Propylene Glycols; Receptors, Lysosphingolipid; Rett Syndrome; Sphingosine | 2012 |